6887-96-3

Basic information

• Product Name: Piperazine, 1-(4,4-diphenylbutyl)-
• CAS NO: 6887-96-3
• Molecular Formula: C20H26N2
• Molecular Weight: 294.44
• Mol File: 6887-96-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Piperazine, 1-(4,4-diphenylbutyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 1-(4,4-diphenylbutyl)-(6887-96-3)
• EPA Substance Registry System: Piperazine, 1-(4,4-diphenylbutyl)-(6887-96-3)

Safety Data

• Hazardous Substances Data: 6887-96-3(Hazardous Substances Data)

Upstream product

• 120-43-4 4-ethoxycarbonylpiperazine 
• 3312-08-1 1,1-diphenyl-4-chlorobutane 
• 108-10-1 4-methyl-2-pentanone 
• 929219-66-9 4,4-diphenylbutyl 4-methylbenzenesulfonate 
• 86419-96-7 2-(2,2-diphenyl-ethyl)-malonic acid 
• 103870-65-1 4-(4,4-diphenyl-butyl)-piperazine-1-carboxylic acid ethyl ester 
• 6944-27-0 2,2-diphenylethyl 4-methylbenzenesulfonate 
• 56740-71-7 4,4-diphenyl-1-butanol 
• 14578-67-7 4,4-diphenylbutanoic acid 
• 3469-00-9 methyl 2,2-diphenylacetate 
• 10347-50-9 methyl 4,4-diphenylbutanoate 
• 1883-32-5 2,2-diphenyl ethanol 
• 117-34-0 2,2-diphenylacetic acid 

Downstream Products

• 1092850-47-9 10-[4-(4-(4,4-diphenylbutyl)piperazino)butyl]phenothiazine 

Relevant articles and documents

New 1,3-dioxolane and 1,3-dioxane derivatives as effective modulators to overcome multidrug resistance

Multidrug resistance (MDR) to antitumor agents represents a major obstacle to a successful chemotherapy of cancer. Overexpression of P-glycoprotein (p-gp) seems to be the major factor responsible for MDR. A large number of chemically unrelated compounds are known to interact with p-gp resulting in a decreasing resistance. In our efforts related to structure-activity studies of new potential MDR reversal agents we synthesized a series of compounds that differ in the aromatic core structure, the linker, and the basic moiety. For our search of new aromatic core structures we synthesized novel 2,2-diphenyl-1,3-dioxolane, 2,2- diphenyl-1,3-dioxane, and 4,5-diphenyl-1,3-dioxolane derivatives. A range of lipophilic linker structures and protonable basic moieties were synthesized and investigated to optimize the structure of the potential MDR-modulators. The compounds were tested in vitro using human Caco-2 cells. Both the cytotoxicity of the synthons and their ability to resensitize the cells were determined with a MTT assay. The results show that at low concentration various substances reverse tumor cell MDR. Some of the new structures show better effects than established modulators like trifluoperazine.